Phaseline

Companies › Axsome Therapeutics

Axsome Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 16 registered trials: 10 Phase 3, 4 Phase 4, 2 Phase 2; Other, Psychiatry, Genitourinary, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Bupropion (AXS-05)
Dopamine transporter inhibitor; Norepinephrine transporter inhibitor
SLC6A3, SLC6A2Phase 4Major Depressive Disorder; Smoking Cessation; Major Depressive Disorder (MDD); Cigarette Smoking-Related Carcinoma …Dec 2027
Solriamfetol Dose A
Dopamine and norepinephrine reuptake inhibitor
SLC6A3, SLC6A2Phase 3Excessive Sleepiness; Binge-Eating Disorder; ADHD; Major Depressive Disorder With Excessive Daytime Sleepiness SymptomsDec 2026
Esreboxetine (AXS-14)
Norepinephrine transporter inhibitor
SLC6A2Phase 3FibromyalgiaMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06223880Bupropion (AXS-05)Phase 4Major Depressive DisorderPsychiatryMar 2026
NCT06568367Solriamfetol Dose APhase 3Excessive SleepinessOtherDec 2026
NCT06413433Solriamfetol Dose APhase 3Binge-Eating DisorderPsychiatryDec 2026
NCT06675851Bupropion (AXS-05)Phase 4Major Depressive Disorder (MDD)PsychiatryDec 2026
NCT03996265Bupropion (AXS-05)Phase 3Hematopoietic and Lymphatic System NeoplasmOncologyDec 2026
NCT07523048Bupropion (AXS-05)Phase 2Major Depressive Disorder (MDD)PsychiatryJan 2027
NCT05732272Bupropion (AXS-05)Phase 3Smoking CessationOtherJan 2027
NCT04422652Bupropion (AXS-05)Phase 2Chronic Kidney DiseasesGenitourinaryApr 2027
NCT05273996Bupropion (AXS-05)Phase 4Major Depressive DisorderPsychiatryApr 2027
NCT06233799Bupropion (AXS-05)Phase 3Methamphetamine-dependencePsychiatryApr 2027
NCT07766655Bupropion (AXS-05)Phase 3Smoking CessationOtherDec 2027
NCT07398417Esreboxetine (AXS-14)Phase 3FibromyalgiaOtherMar 2028
NCT07717879Solriamfetol Dose APhase 3ADHDPsychiatryJun 2028
NCT07717892Solriamfetol Dose APhase 3ADHDPsychiatryJun 2028
NCT07484217Solriamfetol Dose APhase 3Major Depressive Disorder With Excessive Daytime Sleepiness SymptomsPsychiatryDec 2028
NCT04604509Bupropion (AXS-05)Phase 4Cigarette Smoking-Related CarcinomaOncologyDec 2028

From the company's SEC filings

Cash of $314m on 2026-09-30; operating cash outflow about $85m a year; runway about 44 months at that burn, to Jun 2030; 6 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Specialist investors

Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

SLC6A2 (3) SLC6A3 (2)

Companies with the same targets

Currax Pharmaceuticals Otsuka Resilient Pharmaceuticals Remedy Definium Therapeutics US Supernus Pharmaceuticals Theravance Biopharma CSPC ZhongQi Pharmaceutical Technology Primus Pharmaceuticals AlgoTherapeutix

Companies built like this

Primus Pharmaceuticals Palvella Therapeutics Definium Therapeutics US Adneuris Therapeutics Sound Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.